Biltmore Family Office’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.82M | Sell |
14,226
-176
| -1% | -$22K | 0.25% | 70 |
|
|
2025
Q4 | $1.76M | Sell |
14,402
-1,068
| -7% | -$122K | 0.24% | 70 |
|
|
2025
Q3 | $1.55M | Sell |
15,470
-1,429
| -8% | -$129K | 0.22% | 73 |
|
|
2025
Q2 | $1.4M | Sell |
16,899
-526
| -3% | -$42K | 0.24% | 71 |
|
|
2025
Q1 | $1.41M | Sell |
17,425
-735
| -4% | -$65.7K | 0.24% | 70 |
|
|
2024
Q4 | $1.64M | Sell |
18,160
-996
| -5% | -$96.5K | 0.27% | 64 |
|
|
2024
Q3 | $1.89M | Buy |
19,156
+1,009
| +6% | +$99.1K | 0.32% | 56 |
|
|
2024
Q2 | $1.68M | Buy |
18,147
+725
| +4% | +$65K | 0.31% | 56 |
|
|
2024
Q1 | $1.65M | Buy |
17,422
+2,461
| +16% | +$228K | 0.33% | 55 |
|
|
2023
Q4 | $1.34M | Sell |
14,961
-15,031
| -50% | -$1.12M | 0.28% | 63 |
|
|
2023
Q3 | $2.19M | Buy |
29,992
+1,950
| +7% | +$156K | 0.5% | 37 |
|
|
2023
Q2 | $2.33M | Buy |
28,042
+778
| +3% | +$65.1K | 0.49% | 34 |
|
|
2023
Q1 | $2.08M | Sell |
27,264
-4,217
| -13% | -$350K | 0.44% | 38 |
|
|
2022
Q4 | $2.61M | Buy |
31,481
+4,246
| +16% | +$344K | 0.54% | 29 |
|
|
2022
Q3 | $2.16M | Buy |
27,235
+6,679
| +32% | +$563K | 0.49% | 32 |
|
|
2022
Q2 | $1.53M | Sell |
20,556
-7,281
| -26% | -$547K | 0.38% | 48 |
|
|
2022
Q1 | $2.5M | Sell |
27,837
-12,477
| -31% | -$1.15M | 0.54% | 32 |
|
|
2021
Q4 | $4.51M | Buy |
40,314
+36,722
| +1,022% | +$4.43M | 0.86% | 19 |
|
|
2021
Q3 | $452K | Sell |
3,592
-420
| -10% | -$54.1K | 0.11% | 111 |
|
|
2021
Q2 | $543K | Sell |
4,012
-67
| -2% | -$8.81K | 0.15% | 94 |
|
|
2021
Q1 | $553K | Buy |
4,079
+157
| +4% | +$23.5K | 0.17% | 87 |
|
|
2020
Q4 | $552K | Buy |
3,922
+462
| +13% | +$59.2K | 0.17% | 83 |
|
|
2020
Q3 | $386K | Sell |
3,460
-377
| -10% | -$42.3K | 0.22% | 93 |
|
|
2020
Q2 | $430K | Buy |
3,837
+107
| +3% | +$10.5K | 0.26% | 90 |
|
|
2020
Q1 | $289K | Sell |
3,730
-887
| -19% | -$78.5K | 0.19% | 111 |
|
|
2019
Q4 | $439K | Sell |
4,617
-47,929
| -91% | -$4.15M | 0.18% | 108 |
|
|
2019
Q3 | $4.01M | Sell |
52,546
-235
| -0.4% | -$19.5K | 1.73% | 14 |
|
|
2019
Q2 | $4.63M | Buy |
52,781
+5,615
| +12% | +$479K | 2.51% | 7 |
|
|
2019
Q1 | $4.27M | Buy |
47,166
+3,520
| +8% | +$299K | 2.17% | 9 |
|
|
2018
Q4 | $3.13M | Buy |
43,646
+12,419
| +40% | +$1M | 1.77% | 16 |
|
|
2018
Q3 | $2.99M | Sell |
31,227
-55
| -0.2% | -$5.33K | 1.43% | 24 |
|
|
2018
Q2 | $2.98M | Buy |
31,282
+10,752
| +52% | +$988K | 1.48% | 22 |
|
|
2018
Q1 | $1.8M | Buy |
+20,530
| New | +$1.87M | 0.8% | 40 |
|
Other funds holding XBI
Biltmore Family Office's XBI Position: Q1 2026 in Review
Biltmore Family Office reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.2% in Q1 2026, selling an estimated $22K and leaving 14,226 shares worth $1.82M. The position accounts for 0.25% of the portfolio, ranked #70.
Biltmore Family Office first reported a position in XBI in Q1 2018 and has held it in 33 quarters since. The position peaked at $4.63M in Q2 2019. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Biltmore Family Office held 14,226 shares of State Street SPDR S&P Biotech ETF worth $1.82M as of Q1 2026.
- Biltmore Family Office sold 176 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $22K.
- State Street SPDR S&P Biotech ETF made up 0.25% of Biltmore Family Office's portfolio in Q1 2026, its #70 holding.
- Biltmore Family Office first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 33 quarters since.
- Biltmore Family Office's State Street SPDR S&P Biotech ETF position peaked at $4.63M in Q2 2019.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Biltmore Family Office's 13F filing for Q1 2026, filed 11 May 2026.